Méniére's Disease Vertigo Not Controlled by Intratympanic Steroids: What Comes Next
In patients with active Méniére's disease who have not achieved adequate vertigo control following intratympanic steroid injection, a defined next-line intervention exists. The primary clinical goal remains reduction or control of Méniére's disease vertigo attacks.
Previous Treatment — Failure Condition
Intratympanic steroid injection (dexamethasone sodium phosphate or methylprednisolone sodium succinate) was administered but did not achieve the required outcome: improved control of Ménière's disease vertigo. This unmet goal is the basis for escalating to the next treatment line.
Next-Line Approach — Partial Overview
The protocol advances to an intratympanic ablative therapy targeting the inner ear. This approach is supported for patients with active Méniére's disease who have not responded to nonablative treatment. The specific agent, administration details, and full clinical protocol are available in the structured regimen.
References
DOI: 10.1177/0194599820909438
- Clinicians should offer, or refer to a clinician who can offer, intratympanic (IT) gentamicin to patients with active Ménière's disease not responsive to nonablative therapy.
- While there is no specific dosing protocol, the literature supports dosing on a weekly or "as needed" basis, given that there is a lower effect on hearing as compared with high-dose or infusion therapy.
- The goals of MD treatment are to prevent or at least reduce the severity and frequency of vertigo attacks.
View source ↗